Tokyo – (work wire) – Elix, Inc. (CEO: Shinya Yuki/HQ: Tokyo, hereinafter referred to as “Elix”) and SEEDSUPPLY Inc. (Executive Director: Naoki Tarui/HQ: Kanagawa, hereinafter referred to as “SEEDSUPPLY”) hereby declares the commencement of the joint search.
SEEDSUPPLY (https://www.seedsupply.co.jp/) proposes an agile small-molecule drug discovery process that uses binder selection technology as a proprietary compound screening method. This technology can perform complex screening of any protein or RNA, thus providing drug discovery seeds for various drug discovery targets, including those for which measuring biochemical activity is challenging. In addition, a binding compound database created for specific drug discovery target classes will be used for target identification, improving the efficiency and success rate of drug discovery processes. Moreover, the database offers a wider applicability.
Elix (https://www.elix-inc.com/) is an AI-powered drug discovery company whose mission is to “rethink drug discovery”. To reduce cost and time while increasing the success rate of the drug discovery pipeline, Elix is focusing on using machine learning in projects targeting drug companies, universities, and research institutes. Elix has developed and released “Elix Discovery™”, the all-in-one platform for AI drug discovery, providing everything from property prediction models and molecular design, to consulting and implementation support in one package (https://www.elix-inc.com/news /newsrelease/1620/). In addition to providing drug discovery support at the moment, Elix is also considering intravenous drug discovery in the future.
In this joint research project, SEEDSUPPLY will use Elix’s proprietary artificial intelligence technology with the goal of significantly increasing the efficiency of screening processes. Elix will integrate SEEDSUPPLY’s wealth of data, particularly its data on key drug discovery targets such as transmembrane proteins, into an AI training pipeline, thus developing technology in silico Techniques for checking vehicles with superior properties.
Elix and SEEDSUPPLY aim to leverage their respective strengths to reduce the cost and time of small molecule drug discovery and address targets that have proven challenging for traditional drug discovery methods.
Comments from Elix CEO Shinya Yuki
By combining data obtained through SEEDSUPPLY technology with our own AI models, we hope to find more unique technological advances. We believe this technology will offer great possibilities in screening for extremely challenging targets at low cost in short times, and in effectively searching vast chemical areas.
Comments from SEEDSUPPLY CEO Naoki Tarui
The binding complex database of our company is of the highest quality, because all its contents were measured using the same method. By combining it with Elix’s superior AI technology, we hope to bring new advances in AI drug discovery technology.